Black Patients Face Disparities for CGMs, Insulin Pumps
Drug Topics
NOVEMBER 29, 2022
New research adds more evidence of Black patients facing disparities in diabetes care.
Tue.Nov 29, 2022
503 
Evommune’s unique method of drug discovery is more than skin deep
PharmaVoice
NOVEMBER 29, 2022
The biotech is using human skin squares from plastic surgery to find the best immunological molecules for solving conditions like dermatitis.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Does Your Vaccine Storage System Protect Patients and Your Business?
Drug Topics
NOVEMBER 29, 2022
Drug Topics® is joined by Madeline Camejo, MS, PharmD, to vaccine storage systems, the common challenges linked to them, and the best practices that pharmacies should adopt to ensure safe storage.
After three years in prison, ‘CRISPR babies’ scientist is attempting a comeback
STAT
NOVEMBER 29, 2022
He Jiankui, the Chinese biophysicist who created the first gene-edited children , had been quiet since completing a three-year prison sentence in April, leaving many to wonder whether he had plans to return to scientific research. Earlier this month, we got his answer. On Nov. 9, He posted photos to Twitter of himself sitting at a computer in a white office.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Examining the Impact of Vaccine Hesitancy
Drug Topics
NOVEMBER 29, 2022
Taking a look at the causes of vaccine hesitancy and the effects of vaccine hesitancy on public health.
STAT+: Detailed data on Alzheimer’s therapy from Eisai, Biogen hold up to scientific scrutiny
STAT
NOVEMBER 29, 2022
SAN FRANCISCO — A closely watched new treatment for Alzheimer’s disease held up to scrutiny in a detailed scientific presentation Tuesday, as its developers, partners Eisai and Biogen, begin the lengthy process of turning this medicine into what they hope could be a groundbreaking therapy. The drug, lecanemab, slowed the cognitive and functional decline of patients with early-stage Alzheimer’s by 27% relative to placebo in a roughly 2,000-volunteer clinical trial.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
UnitedHealth Group expects to bring in nearly $360B in revenue for 2023
Fierce Healthcare
NOVEMBER 29, 2022
UnitedHealth Group expects to bring in nearly $360B in revenue for 2023. hlandi. Wed, 11/30/2022 - 00:11.
Bladder Cancer Indication for Tecentriq Withdrawn
Drug Topics
NOVEMBER 29, 2022
A confirmatory trial of Tecentriq in urothelial carcinoma failed to meet the co-primary endpoint of overall survival.
One biotech’s approach to science-driven innovation
PharmaVoice
NOVEMBER 29, 2022
Why some in the industry say fostering creativity in drug development is all about work structures.
Trauma-Informed Care Is an Essential Skill for Pharmacists
Pharmacy Times
NOVEMBER 29, 2022
Students can begin learning about treating patients with trauma early.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
NHS expedites rollout of Bayer’s darolutamide for prostate cancer
Pharmaceutical Technology
NOVEMBER 29, 2022
The National Health Service (NHS) in England, UK, has expedited the rollout of Bayer ’s new life-extending drug, darolutamide, to treat the most advanced kinds of prostate cancer that have spread to other body parts. With the latest development, NHS will become the first healthcare system in Europe to offer this drug to prostate cancer patients. Nearly 9,000 men with prostate cancer will be eligible to receive this treatment.
Experimental Type 1 Diabetes Drug Could Slow Growth of Rare Mantle Cell Lymphoma
Pharmacy Times
NOVEMBER 29, 2022
An experimental drug could help scientists understand the development of mantle cell lymphoma and potentially increase overall survival.
AstraZeneca enters $320m deal to acquire Neogene
Pharmaceutical Technology
NOVEMBER 29, 2022
AstraZeneca has signed an agreement for the acquisition of all outstanding equity of clinical-stage biotechnology firm Neogene Therapeutics in a deal totalling up to $320m. Neogene focuses on discovering, developing and producing next-generation T-cell receptor therapies (TCR-Ts) that provide a new cell therapy approach for fighting cancer. TCR-Ts can detect intracellular targets such as cancer-specific mutations to unlock targets which were not accessible earlier using cell therapies.
Parents, Clinicians Can Take Steps to Manage Food Allergies During the Holidays
Pharmacy Times
NOVEMBER 29, 2022
Parties and get-togethers often present challenges for patients with allergies, particularly with home-cooked food that may have unclear ingredients.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Expanding ketamine’s horizons to treat rare neurological disorders
Pharmaceutical Technology
NOVEMBER 29, 2022
For several decades, researchers have been investigating the role of ketamine in treating depression. Now, efforts are underway to study ketamine’s effects in Parkinson’s disease, fibromyalgia, and Rett syndrome. On November 14, the Canadian developer PharmaTher announced positive data from a Phase I/II study where ketamine was used to treat levodopa-induced dyskinesia in Parkinson’s disease.
Laugh Off Burnout? It May Not Be That Simple, But It Can Certainly Help
Pharmacy Times
NOVEMBER 29, 2022
Comedy has taught me several keys that have helped alleviate and manage burnout.
Resistance to FDA’s opioid-disposal plan raises concerns about CADCA, a powerful advocacy group
STAT
NOVEMBER 29, 2022
At its surface, it seems like a simple problem with a simple solution. Across the country, medicine cabinets are littered with unused, potentially addictive opioids. So the federal government wants to distribute prepaid envelopes alongside new painkiller prescriptions, allowing Americans to mail back their leftovers. But the seemingly innocuous proposal has generated opposition from a surprising source: the Community Anti-Drug Coalitions of America, a powerful nonprofit organization that has dom
RaDaR Assay May Effectively Detect Minimal Residual Disease in Breast Cancer Patients, Improve Outcomes
Pharmacy Times
NOVEMBER 29, 2022
Data to be presented at the45th Annual San Antonio Breast Cancer Symposium suggest that the novel sequencing test can detect signs of disease recurrence across breast cancer subtypes, improving outcomes.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Could a potential recession diminish influencers’ influence?
Drug Store News
NOVEMBER 29, 2022
A marketing expert predicts that brands will continue to invest in influencer marketing in 2023 despite an economic downturn and revised marketing budgets.
Study Highlights Changes to the Brain Caused by Migraines
Pharmacy Times
NOVEMBER 29, 2022
Research into how perivascular spaces contribute to migraine could help better understand the complexities of how these headaches occur.
Company profile: NeoImmuneTech
pharmaphorum
NOVEMBER 29, 2022
NeoImmuneTech, Inc. CEO: Dr Se Hwan Yang, PhD. Headquarters: Rockville, MD, USA (2400 Research Blvd., Suite 250, Rockville, MD 20850). Locations: 3 (US HQ, Korea office, Korea R&D center). Number of employees: 90+ (as of Oct. 31, 2022). Main asset: NT-I7 (efineptakin alfa), a long-acting human IL-7. Number of on-going clinical trials: 14. Creation: Jan. 29, 2014.
Derazantinib Shows Clinical Benefit, Manageable Safety Profile in Patients With Cholangiocarcinoma
Pharmacy Times
NOVEMBER 29, 2022
Derazantinib is an investigational oral inhibitor of FGFR1, FGFR2, and FGFR3 in patients with locally advanced or metastatic intrahepatic cholangiocarcinoma.
STAT+: Horizon Therapeutics in acquisition talks with Amgen, Janssen, and Sanofi
STAT
NOVEMBER 29, 2022
Amgen, Janssen, and Sanofi are in talks to acquire Horizon Therapeutics, the Irish drugmaker confirmed Monday. Horizon confirmed the discussions following a report in the Wall Street Journal, adding that the conversations were “highly preliminary.
Study Shows Hormonal Contraceptives May Affect Adolescent Brain Development
Pharmacy Times
NOVEMBER 29, 2022
Prior research has associated early adolescent use of hormonal contraceptives with the risk of depression in adulthood.
Nine Questions For Choosing a Psychedelic Retreat
The Spirit Pharmacist
NOVEMBER 29, 2022
Choosing a Psychedelic Retreat. Attending a psychedelic retreat can be a great way to experience and benefit from psychedelics. The opportunity to travel, change scenery, take time and space for yourself, and experience psychedelics in controlled or ritualistic environments can create powerful effects. Yet, I've noticed that oftentimes when I'm consulting with a person that is considering attending a psychedelic retreat, that they are often unsure how to evaluate if the retreat is a good fit for
Perform Drug-Drug Interaction Assessments at Every Visit
Pharmacy Times
NOVEMBER 29, 2022
Pharmacists should evaluate medications for potential problems at patient meetings to improve safety.
STAT+: PhRMA, once invincible in Washington, has lost its edge
STAT
NOVEMBER 29, 2022
WASHINGTON — PhRMA has a reputation in Washington for might, for money, for scorched-earth tactics, and for fighting even the tiniest of policy changes. The pharmaceutical industry’s lobbying arm raised hell, for example, when lawmakers asked it to cover a slightly larger share of seniors’ drug costs. It spent years refusing to concede even minimal tweaks to an obscure bill related to generic competition.
The State of Pharmacy Benefit Managers [2022 Report]
PioneerRx
NOVEMBER 29, 2022
The pharmacy industry is complex, both in healthcare and commerce. Learn about what independent pharmacists feel about the role of a pharmacy benefit manager in.
STAT+: Pharmalittle: PhRMA trade group is losing its edge; Eisai CEO tries to silence critics of Alzheimer’s drug
STAT
NOVEMBER 29, 2022
Hello, everyone, and how are you today? Gray skies are hovering over the Pharmalot campus this morning, but our spirits remain sunny. And why not? Once again, we are reminded of a favorite bit of wisdom from the Morning Mayor: “Every new day should be unwrapped like a precious gift.” So go ahead — tug on the ribbon, and join us for a delicious cup of stimulation.
CMS threatens citations for hospitals without appropriate workplace safety practices
Fierce Healthcare
NOVEMBER 29, 2022
CMS threatens citations for hospitals without appropriate workplace safety practices. dmuoio. Tue, 11/29/2022 - 12:17.
CVS Health rolls out time-delay safes to an additional 13 states
Drug Store News
NOVEMBER 29, 2022
The company has implemented technology to prevent pharmacy robberies in 45 states across the U.S.
AstraZeneca to acquire Neogene for $320 million
European Pharmaceutical Review
NOVEMBER 29, 2022
AstraZeneca has announced it will acquire biotech Neogene Therapeutics Inc. for up to $320 million, to boost development of next-generation oncology T-cell receptor therapies (TCR-Ts) for patients with solid tumours, helping to increase access to cell therapies. T-cell receptor therapies. TCR-Ts are an emerging therapeutic to treat cancer. Most current cell therapy approaches for oncology focus on modifying the immune system’s T cells to recognise proteins on the surface of cancer cells.
Is cyclobenzaprine safe for dogs?
The Checkup by Singlecare
NOVEMBER 29, 2022
Can dogs take cyclobenzaprine? | Cyclobenzaprine dosage for dogs | Side effects | Safety. If you’ve ever sprained your ankle or strained a muscle, you might be familiar with the medication cyclobenzaprine. Cyclobenzaprine , sold under the brand name Flexeril or Fexmid , is a prescription drug and muscle relaxant that manages muscle spasms and blocks pain by inhibiting nerve impulses being transmitted to the brain.
Let's personalize your content